Hiroshi Isobe

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations

Medicine, Oncology, Pharmacology +13

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo et al. · Annals of Oncology · 2012 · 554 citations

Medicine, Oncology, Pharmacology +15

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Hajime Asahina, K Yamazaki, Ichiro Kinoshita et al. · British Journal of Cancer · 2006 · 278 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

Sayaka Onoda, Noriyuki Masuda, Takashi Seto et al. · Journal of Clinical Oncology · 2006 · 227 citations · Full text

Medicine, Oncology, Pharmacology +15

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q

Satoshi Watanabe, Yuji Minegishi, Hirohisa Yoshizawa et al. · Journal of Thoracic Oncology · 2014 · 204 citations · Full text

Medicine, Oncology, Pharmacology +12